Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus: A Randomized Clinical Trial
The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project.
The objective of this study was to evaluate the effect of insulin eye drops at a concentration of 50 IU/ml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial was conducted with two groups, one being the control group, in which researchers compared the epithelial healing rate in mm²/h between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure were invited to participate.
The study was designed to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients from the Keratoconus Clinic of the Hospital de Clínicas, State University of Campinas (UNICAMP), Brazil, with a diagnosis of keratoconus and an indication for corneal crosslinking were evaluated with visual acuity, refraction, slit-lamp biomicroscopy, Goldmann applanation tonometry, corneal specular microscopy (EM-3000, Tomey) for endothelial cell count, and corneal tomography (Pentacam HR, Oculus).
Eligible patients who signed the informed consent form (with the legal guardian also signing for participants younger than 18 years) underwent crosslinking. After the procedure, participants were allocated to two groups (insulin and placebo) by block randomization with blocks of four, stratified by sex. The random sequence was generated at random.org/lists and concealed in sealed opaque envelopes prepared by an independent assistant. Envelopes were opened sequentially at enrollment by investigators who did not take part in outcome assessment. One participant underwent crosslinking in both eyes, which were allocated to different groups; the eye was the unit of analysis.
Crosslinking was standardized for all participants and performed by third-year ophthalmology residents supervised by attending physicians. Central 8.0-mm epithelial debridement was performed with an optical zone marker of the same diameter: 30% alcohol was applied within the marker for 10 seconds and dried with an ophthalmic sponge, and the epithelium was removed with a corneal scarifier spatula. Riboflavin 0.1% (400 mOsm) in a hydroxypropyl methylcellulose vehicle was used, with UVA irradiation at 9 mW/cm² for 10 minutes (fluence 5.4 J/cm²) using the Eyelink Crosslink device (Eyetec, São Carlos, Brazil). At the end of the procedure, the size and shape of the debrided area were checked with the 8.0-mm marker, and participants whose debridement did not meet this standard were excluded.
The insulin group received NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, Brazil) four times daily, and the placebo group received 0.5% methylcellulose eye drops (Eye Pharma), the vehicle of the insulin formulation, four times daily, until complete epithelial healing. The bottles were identical and were labeled on the prescription as "compounded eye drops". Participants and outcome assessors were masked to group allocation. Both groups received moxifloxacin 5 mg/mL every 6 hours (Oftalmox; Geolab), prednisolone acetate 10 mg/mL every 6 hours (Ster; União Química), 0.15% sodium hyaluronate every 4 hours (Hyabak; Laboratoires Théa) and a silicone hydrogel bandage contact lens (Air Optix plus HydraGlyde; Alcon) until complete epithelial healing. Moxifloxacin and the study eye drops were then discontinued, and prednisolone was tapered weekly until one month after the procedure.
Crosslinking was always performed on Tuesdays, and assessments took place 18, 42 and 66 hours after the procedure (postoperative days 1 to 3). If epithelialization was incomplete at 66 hours, a further visit was scheduled on postoperative day 6 and every 48 hours thereafter until complete epithelialization. At each visit, the epithelial defect was photographed with the Keratograph 5M (OCULUS) and slit-lamp biomicroscopy was performed. The defect area was measured with ImageJ software by an investigator masked to allocation and reviewed independently by a second masked investigator. Complete epithelial healing was defined as the absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed by two examiners on slit-lamp examination.
The primary outcome is the corneal epithelialization rate (mm²/h). Secondary outcomes are time to complete epithelialization and adverse events, in addition to endothelial cell density. Later follow-up visits took place at 30 and 60 days after crosslinking.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13.083-887
- State University of Campinas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 14 years or older
- Diagnosis of keratoconus with an indication for corneal crosslinking
Exclusion Criteria:
- Diabetes mellitus
- Dry eye disease
- Limbal stem cell deficiency
- Glaucoma
- Allergy to insulin or methylcellulose
- Irregular epithelial debridement and/or debridement other than 8.0 mm during the crosslinking procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Insulin
NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, SP, Brazil), one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen. |
Insulin eye drops in the postoperative prescription for corneal crosslinking
Other Names:
|
|
Placebo Comparator: Placebo
0.5% methylcellulose eye drops (Eye Pharma, São Paulo, SP, Brazil), the vehicle of the insulin formulation, one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen. |
Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Corneal Epithelial Healing Rate
Time Frame: From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.
|
Rate of corneal re-epithelialization (mm²/h), calculated as the epithelial defect area at the first postoperative assessment (18 hours) divided by the time elapsed until complete epithelialization. Defect area measured on Keratograph 5M (OCULUS) images with ImageJ software by masked investigators. |
From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endothelial cell count
Time Frame: 60 days
|
Endothelial cell count loss in each group, if any |
60 days
|
|
Incidence of corneal haze
Time Frame: 60 days.
|
Incidence of corneal haze in each group. |
60 days.
|
|
Time to complete epithelialization
Time Frame: From crosslinking until complete epithelialization.
|
Time (hours) from crosslinking to the first assessment at which complete epithelial closure was documented (absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed on slit-lamp examination). Closure could only be ascertained at scheduled visits. |
From crosslinking until complete epithelialization.
|
|
Adverse events
Time Frame: From crosslinking until the end of follow-up.
|
Number of eyes with ocular adverse events (e.g., infectious keratitis, sterile infiltrates, persistent epithelial defect, allergic reaction to study eye drops) recorded at each study visit. |
From crosslinking until the end of follow-up.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Epithelial Defect Area
Time Frame: 18, 42 and 66 hours after crosslinking.
|
Area of the corneal epithelial defect (mm²) measured on Keratograph 5M images with ImageJ software. |
18, 42 and 66 hours after crosslinking.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Monica Alves, PhD, State University of Campinas (Unicamp)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Keratoconus
- Corneal Diseases
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Pharmaceutical Solutions
- Peptide Hormones
- Peptides
- Amino Acids, Peptides, and Proteins
- Pharmaceutical Preparations
- Pharmacologic Actions
- Chemical Actions and Uses
- Therapeutic Uses
- Solutions
- Specialty Uses of Chemicals
- Insulin, Long-Acting
- Insulins
- Pancreatic Hormones
- Proinsulin
- Insulin
- Ophthalmic Solutions
- Insulin, Isophane
Other Study ID Numbers
Other Study ID Numbers
- 77229224.8.0000.5404
- Topical Insulin (Other Identifier: Unicamp)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The de-identified dataset analyzed during the current study is available from the corresponding author on reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.